SOPHiA GENETICS and AstraZeneca Expand AI Collaboration for Breast Cancer Treatment

August 05, 2025
SOPHiA GENETICS has announced an expanded partnership with AstraZeneca to leverage AI for improving breast cancer patient outcomes, as stated in a press release.

SOPHiA GENETICS has announced an expansion of its collaboration with AstraZeneca to enhance breast cancer treatment outcomes using artificial intelligence, announced in a press release. This multi-year partnership will utilize SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy and real-world impact of therapies for certain types of breast cancer.

The collaboration aims to develop a bespoke AI-powered predictive model to optimize treatment outcomes for breast cancer patients. SOPHiA GENETICS's AI Factories will analyze multimodal healthcare data, including genomics, imaging, and clinical data, to provide insights that can improve patient prognosis and treatment response.

AstraZeneca will use these insights to enhance clinical decision-making and address critical knowledge gaps in breast cancer treatment. The partnership will also focus on generating real-world evidence in Europe and North America to uncover key drivers of treatment efficacy.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

08/09
Body Vision Medical's LungVision Approved in Singapore for Lung Cancer Diagnosis
08/09
Pager Health Introduces AI-Powered Behavioral Health Agent
08/09
ARMR Sciences Launches $30M Capital Raise for Biodefense Platform
08/09
Ellipsis Health Joins CMS Health Tech Ecosystem for AI Transformation
08/09
Caris Life Sciences Enhances Cancer Diagnosis with AI-Based Tool

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like